TWIST BIOSCIENCE CORP

Twist Bioscience insider sales reveal routine liquidity moves, not a market shift—investors should focus on earnings, pipeline, and future filings.

Twist Bioscience CEO sells 3,000 shares in a structured 10b5‑1 plan – a routine move amid strong growth and positive market sentiment.

Explore Twist Bioscience’s CEO insider trades—key signals on synthetic biology trends, market sentiment, and investor insight into the biotech sector’s growth.